MedTrace Logo

Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

NCT00827359 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2021-02-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if certain features of tumor specimens sampled prior to therapy can predict for the likelihood of responding to everolimus.

Conditions

Interventions

DRUG

Everolimus

Tablet form taken orally once a day

Sponsors & Collaborators

Principal Investigators

  • David F McDermott, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2018-01-31
Completion
2018-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00827359 on ClinicalTrials.gov